Our purpose was to evaluate the efficacy of a new formulation of methylcellulose, preservative-free 0.5% hydroxypropyl methylcellulose (HPMC), for the treatment of dry eye. In the clinical part of our study, two groups of dry-eye patients, those with Sjogren's syndrome (SS) and those without (non-SS), were treated topically with 0.5% HPMC and evaluated for symptoms, ocular surface vital staining, tear breakup time (BUT), and tear evaporation rate from the ocular surface at 40% ambient humidity (TEROS40). In the in vitro part of the study, rose bengal uptake was measured in human conjunctival epithelial cells, which were cultured and incubated with or without 0.5% HPMC. Although symptoms improved in both groups, rose bengal and fluorescein staining and BUT improved significantly only in the SS group. TEROS40 increased for 30 min after instillation of 0.5% HPMC, but not after the use of 0.1% sodium hyaluronate or salinebased artificial tears. Rose bengal uptake by cultured conjunctival epithelial cells was blocked by 0.5% HPMC. These findings suggest that 0.5% HPMC provides long coverage of and protection for the ocular surface. Patients with severe dry eye, such as in SS, are good candidates for this treatment.
punctum plugs (2). However, in severe cases, especially with Sjogren's syndrome (SS), symptoms and ocular surface damage are sometimes uncontrollable and the patients' quality of life is greatly limited.
The severity of ocular surface damage may depend on the presence of stimulated tears, which reflects the maximal ability of the lacrimal gland to moisten the eye. In SS this gland typically is infiltrated and destroyed by lymphocytes. Tsubota (3) introduced a nasal stimulation method to obtain the maximal stimulated tearing and reported a lack of stimulated tearing in SS, accompanied by severe rose bengal staining of the ocular surface. Treatment of SS dry eye is thus complicated because tear components, which are crucial for wound healing and maintenance of ocular surface integrity, are not well supplied.
Several investigators have tried to develop new treatments based on the immunologic pathogenesis of SS. Cyclosporin A improved severe dry eye in dogs, presumably by inhibiting T cells in lacrimal glands (4). There are many reports that suggest that Epstein-Barr virus (EBV) plays a role in SS (5,6). Interferon-a, an inhibitor of EBV, was used to treat dry mouth in SS patients and was found to improve saliva secretion (7). However, further work is required to determine the safety and efficacy of these drugs for clinical application. In the present study, we were interested in finding a better artificial tear preparation using currently available materials to improve the quality of life of SS patients.
Many kinds of artificial tears with a variety of formulations have been developed. Some were intended only to supplement aqueous tears, whereas others, such as fibronectin (8) and hyaluronate (9,10), were designed to accelerate ocular surface wound healing. However, most of these formulations provide only transient relief for SS dry eye, since they don't remain on the ocular surface for long and require frequent instillation. Many viscous agents, such as poly vinyl alcohol (PVA) and methylcellulose (MC), have been employed to prolong drug retention on the ocular surface (11, 12) and are now widely used as lubricants for dry eye. Even though biochemical and rheological studies (13) (14) (15) suggest that these agents are good tear substitutes, there have been very few clinical reports (16, 17) that have shown a significant improvement in symptoms as well as in ocular surface damage with these drugs.
The ability of these polymers to remain on the ocular surface depends on their concentration, which determines their viscosity. However, increasing viscosity lessens patients' tolerance because the drops may become too sticky, cause discomfort, and temporarily interfere with vision (14). These effects also depend on the severity of dry eye.
MC, the most commonly available ophthalmic polymer solution, includes several kinds of compounds, which share a polymeric backbone of cellulose, a natural carbohydrate that contains a basic repeating structure of anhydroglucose units. The properties of each MC vary depending on substitutions to the backbone (data from Alcon). Grene et al. reported that a carboxy methylcellulose (CMC)based solution is more beneficial for dry eye than a hydroxypropyl methylcellulose (HPMC)-based solution (16). Feenstra and Tseng observed that CMC blocked uptake of rose bengal by cultured epithelial cells (18). In contrast, the advantage of HPMC has not been well elucidated. In this study, we used a new formulation of MC, preservative-free 0.5% HPMC, to treat SS and non-SS dry-eye patients and also examined some of its in vitro properties.
MATERIALS AND METHODS

Patients
Twenty-four dry-eye patients (47 eyes, one enucleated) were recruited into this study. They were divided into two groups according to their ocular and systemic conditions: dry eye associated with SS (27 eyes in 14 patients; three men and 11 women, 50.4 ± 9.1 years old) and dry eye not associated with SS (non-SS; 20 eyes in 10 patients; five men and five women, 53.7 ± 16.4 years old). SS was diagnosed according to the criteria of Fox et al. (19) . Non-SS was diagnosed based on our criteria (20), which required the presence of chronic dryeye symptoms, positive vital staining of the ocular surface [rose bengal score &3 or fluorescein score 5*1), and the presence of tear dynamics abnormality (Schirmer test «5 mm, phenol red thread tear test (21) =£10 mm, tear clearance test (22) =sl:4, or tear breakup time =£5 s].
Basic and stimulated tear secretions, which were determined by the Schirmer test, with anesthesia and with nasal stimulation (3), respectively, were 3.9 ± 3.3 mm and 5.1 ± 6.4 mm for SS and 6.2 ± 5.1 mm and 15.8 ± 12.3 mm for non-SS, indicating that maximal tear secretion from the lacrimal gland was suppressed in SS.
Drug Protocol
The patients were instructed to use a preservative-free 0.5% HPMC (Alcon, Osaka, Japan) four times a day. Symptoms and signs were compared before and 1 month after beginning treatment. Any previous treatments, such as use of protective eyeglasses or other artificial tears, were continued in all patients.
Symptoms
Dry-eye symptoms were evaluated using a questionnaire (Table 1) . Fourteen symptoms were scored 0-5 according to their severity: 0, none; 1, occasional; 2, constant, but mild and putting no restriction on activities of daily living (ADLs); 3, constant and moderate, but no restriction of ADLs; 4, constant and severe, with some restrictions of ADLs; 5, severe restrictions of ADLs. The total score of the three major symptoms in each patient were compared before and after treatment.
Vital Staining of the Ocular Surface
Double vital staining with rose bengal and fluorescein (23) was used to assess ocular surface damage. Two microliters of preservative-free, 1% rose bengal and 1% fluorescein were applied with a micropipette. The ocular surface was divided into seven areas for rose bengal and three areas for fluorescein and scored 0-3 according to the staining intensity. Total scores for each eye were the sums of the rose bengal and fluorescein scores.
Tear Breakup Time (BUT)
BUT was measured with the instillation of 2 (xl of 1% fluorescein. Patients were instructed to keep their eyes open until the first dry spot was observed in the central cornea. The period between the eye opening and the appearance of the first dry spot was measured three times and averaged.
